Under the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10598813
Filing Date		2006-09-13
First Named Inventor LEITO		ЭН
Art Unit		
Examiner Name		
Attorney Docket Number		GB040062

		· ·			U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	stent Number Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines whe Relevant Passages or Rele Figures Appear						
	1	6026073		2000-02	-15	BROWN ET AL					
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT.	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	of sited Desument		Releva		Lines where ges or Relev	
	1	20020080888	A1	2002-06	-27						
	2	20040029553	A1	2004-02	-12						
If you wisl	h to a	ı dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	1. Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i		Kind Code <sup>4</sup>		Name of Patentee or Applicant of cited Document		where Rel	or Relevant	TE
	1	EP0637152			A1	1995-02-01	IBM CORPORATION	ON			
	2	WO03051009			A1	2003-06-19	MESH-NETWORK	S, INC.			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10598813
Filing Date		2006-09-13
First Named Inventor LEITO		Н
Art Unit		
Examiner Name		
Attorney Docket Number		GB040062

	3	EP0948176		A2	1999-06-10	SIEMENS INFORMATION AND COMMUNICATION NETWORKS			
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
			NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								
	1	MAXEMOHUCK, N. F. "DISPERSITY ROUTING IN HIGH-SPEED NETWORKS"; COMPUTER NETWORKS AND ISON SYSTEMS 25 (1993) PP. 645-681;							
	2 LOU ET AL: "A SIMULATION STUDY OF SECURITY PERFORMANCE USING MULTIPATH ROUTING IN AD HOC [ [								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner	Signa	ature				Date Considered			
*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through a									

F

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 2 Applicant is to place a check mark here if English language translation is attached.

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10598813		
Filing Date		2006-09-13		
First Named Inventor LEITO		Н		
Art Unit				
Examiner Name				
Attornov Docket Number		GB040062		

#### CERTIFICATION STATEMENT

Diagon con	37	CFR	1 97	and	1 02	to make	the	appropriate	coloction	v(e)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/11).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paul Im/	Date (YYYY-MM-DD)	2007-05-11
Name/Print	PAUL IM	Registration Number	50418

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, U.S. operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. DIN OTS CRID FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.